Clinical Trial Update: A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of iniparib as a single agent and in combination for solid tumors; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Iniparib (iparib)

Snippet

Sponsor: Sanofi | Conditions: Neoplasm Malignant | Phase 1 | Status: COMPLETED